CJC-1295 + Ipamorelin 20mg — Vial Spec, Reconstitution Math & COA

Overview of the 20mg CJC-1295 + Ipamorelin Vial Specification

In laboratory research, combined secretagogue formulations are utilized to investigate the synergistic activation of growth hormone pathways. A 20mg vial specification typically contains a 1:1 mass ratio consisting of 10mg CJC-1295 (Modified GRF 1-29, without DAC) and 10mg Ipamorelin. This high-capacity fill size is engineered primarily for high-throughput screening, multi-subject rodent trials, or extended cell culture assays where constant volumetric dosing across large test groups is required.

While custom 20mg configurations are utilized in high-volume research applications, PX1 Research standardly supplies the analytical baseline format via our CJC-1295 No DAC / Ipamorelin 10mg Blend. Investigators working with larger 20mg bulk orders or evaluating volumetric concentration models can apply identical reconstitution chemistry principles across all fill sizes. Researchers seeking alternative mass configurations or complementary secretagogues can explore our complete inventory of all peptides.

Dual-Pathway Receptor Synergism in Preclinical Models

The combination of CJC-1295 and Ipamorelin targets two distinct receptor populations located on anterior pituitary somatotrophs. CJC-1295 functions as a synthetic growth hormone-releasing hormone (GHRH) analog that binds directly to the GHRH receptor (GHRHR). Preclinical studies suggest that GHRHR binding activates the adenylate cyclase pathway, elevating intracellular cyclic adenosine monophosphate (cAMP) and initiating the transcription and exocytosis of stored growth hormone (GH).

Ipamorelin acts as a selective agonist of the growth hormone secretagogue receptor (GHS-R1a), also known as the ghrelin receptor. Activation of GHS-R1a operates through a phosphoinositide 3-kinase (PI3K) and intracellular calcium ion pathway. In vitro assays demonstrate that when GHRHR and GHS-R1a are stimulated concurrently, the net release of growth hormone is significantly greater than the additive sum of each peptide acting independently. Crucially, animal studies indicate this secretagogue pairing maintains pulsatile secretion without triggering significant elevations in serum cortisol, ACTH, or prolactin, making it a clean experimental model for evaluating downstream insulin-like growth factor 1 (IGF-1) expression and tissue repair mechanisms.

Reconstitution Mathematics for a 20mg Total Mass Vial

Accurate concentration calculations are vital when reconstituting a combined 20mg lyophilized cake (10mg CJC-1295 + 10mg Ipamorelin). Because the vial contains two distinct active compounds in equal proportion, calculations must track both the total peptide mass concentration and the individual component concentrations. For exact volumetric modeling, researchers should utilize our interactive reconstitution calculator.

The standard concentration metrics across common diluent volumes for a 20mg total mass vial are defined as follows:

1.0 mL Diluent Addition: Yields a total peptide concentration of 20.0 mg/mL. Each 0.1 mL (10 units on a standard U-100 micro-syringe volume equivalent) contains 2.0 mg total peptide (1.0 mg CJC-1295 + 10 mg Ipamorelin).

2.0 mL Diluent Addition: Yields a total peptide concentration of 10.0 mg/mL. Each 0.1 mL contains 1.0 mg total peptide (0.5 mg CJC-1295 + 0.5 mg Ipamorelin). This concentration is frequently selected for medium-sized rodent cohort administration.

3.0 mL Diluent Addition: Yields a total peptide concentration of 6.67 mg/mL. Each 0.1 mL contains 0.67 mg total peptide (0.33 mg CJC-1295 + 0.33 mg Ipamorelin). This dilution reduces working viscosity and minimizes volumetric pipette margin of error.

5.0 mL Diluent Addition: Yields a total peptide concentration of 4.0 mg/mL. Each 0.1 mL contains 0.40 mg total peptide (0.20 mg CJC-1295 + 0.20 mg Ipamorelin), providing optimal accuracy for micro-dosing assays in small-animal research.

Aliquot Planning and Degradation Control

Lyophilized peptides exist in a stable, crystalline state, but once reconstituted into an aqueous phase, they become susceptible to chemical degradation pathways including hydrolysis, deamidation, and methionine oxidation. High-concentration reconstituted solutions (such as 20 mg/mL) must be managed carefully to prevent aggregation or activity loss over prolonged experimental timelines.

To maximize stability, reconstitution should be performed using standard Bacteriostatic Water (0.9% benzyl alcohol) for multi-use laboratory procedures spanning up to 28 days, or sterile 0.9% sodium chloride for immediate in vitro applications sensitive to preservative agents. Reconstituted solutions should be stored at 2°C to 8°C. For long-term study protocols requiring storage beyond 30 days, reconstituted solutions should be aliquoted into single-use low-protein-binding micro-centrifuge tubes and frozen at -20°C or -80°C. Repeated freeze-thaw cycles must be strictly avoided, as the resulting thermal shock induces peptide cleavage and precipitation.

Analytical Testing and Lot-Matched COA Integrity

Multi-component research blends demand rigorous analytical validation to verify that both sequence identities are present in precise ratios without cross-reactivity or unassigned degradation fragments. PX1 Research mandates that every production lot undergo independent testing by an accredited ISO 17025 laboratory using High-Performance Liquid Chromatography (HPLC) and Mass Spectrometry (MS).

The analytical verification process for a dual-peptide blend requires distinct HPLC chromatogram peaks corresponding to the exact retention times of CJC-1295 and Ipamorelin, confirming a overall purity threshold of ≥98.0%. Electrospray Ionization Mass Spectrometry (ESI-MS) confirms the exact molecular weights of both sequences (CJC-1295 No DAC: C152H252N44O42, MW 3367.2 g/mol; Ipamorelin: C38H49N9O5, MW 711.86 g/mol). Furthermore, quantitative Limulus Amebocyte Lysate (LAL) assays verify that bacterial endotoxin levels remain strictly below <0.05 EU/mg. Investigators can download verified reports matching their container lot numbers directly at our COA portal.

Evaluating Vial Mass: 10mg vs. 20mg Selection Strategy

Selecting between a standard 10mg blend vial and a high-capacity 20mg vial depends entirely on the design and throughput of the research trial. A 10mg blend vial (5mg CJC-1295 + 5mg Ipamorelin) is generally optimal for exploratory studies, small animal groups, or assays with intermittent dosing schedules. This format ensures that reconstituted liquid is entirely consumed within the peak stability window, minimizing chemical degradation risk.

Conversely, a 20mg vial format is advantageous for automated liquid-handling systems, high-density animal facility protocols, or continuous cell line treatments. High-mass fill sizes reduce per-assay handling overhead and decrease container-surface adsorption losses across large preparation batches. However, if a research facility cannot consume a 20mg reconstituted volume within 21–28 days, utilizing multiple 10mg vials is scientifically preferable to prevent solution degradation.

Comparative Analysis: Somatotropic Axis Research Peptides

When designing preclinical protocols investigating GH/IGF-1 axis signaling, researchers often compare CJC-1295 + Ipamorelin against single-agent secretagogues or alternate analogs. Understanding differences in half-life, receptor affinity, and pituitary desensitization is critical for choosing the appropriate experimental control.

For example, CJC-1295 DAC incorporates a Drug Affinity Complex (affinity bioconjugate) that covalently binds to circulating serum albumin, extending its biological half-life to several days in rodent models, whereas CJC-1295 No DAC exhibits a half-life measured in minutes to hours. Standard baseline GHRH short-chain analogs like Sermorelin display shorter binding kinetics and lower receptor potency. On the secretagogue arm, older GHRP analogs such as GHRP-2 demonstrate potent GH release but induce dose-dependent increases in cortisol and prolactin via secondary hypothalamic-pituitary-adrenal axis stimulation—an effect absent in highly selective Ipamorelin protocols.

Laboratory Best Practices and Procurement Guidelines

To maintain analytical integrity during reconstitution, laboratory personnel should adhere to aseptic techniques inside a laminar flow cabinet. Diluent should be introduced along the glass wall of the vial to prevent turbulent agitation of the delicate lyophilized matrix. The vial should be gently swirled until complete dissolution is achieved; mechanical vortexing must never be employed as shear stress can disrupt secondary peptide structures.

PX1 Research manufactures all compounds in GMP-compliant, USA-based facilities, ensuring consistent lot-to-lot purity, correct peptide stoichiometry, and zero heavy metal contamination. For broader protocol documentation and scientific literature, review our central research hub. Institutional buyers preparing large-scale animal studies or bulk assay runs can access specialized supply terms through our wholesale program.